Fig 1: MiR-135b-5p directly regulates CNDP1. (A) We employed bioinformatics to ascertain the target interactions between miR-135b-5p and CNDP1. (B) qRT-PCR detecting CNDP1 expression. (C–E) Western blot assessing CNDP1 protein expression levels. (F,G) Verified binding sites between miR-135b-5p and CNDP1. (H–J) Western blot detecting CNDP1 protein expression levels. The uncropped blots are shown in the Supplemental Materials (*** denote p < 0.001).
Fig 2: AS-IV attenuates PD-L1-mediated immune suppression through the miR-135b-5p/CNDP1 axis. (A,B) Western blot assessing CNDP1 protein levels. (C,D) The assessment of surface PD-L1 levels using flow cytometry. (E,F) Flow cytometry analysis of PBMC-mediated cytotoxicity against liver cancer cells. (G–I) Western blot assessing PD-L1 protein expression levels. The uncropped blots are shown in the Supplemental Materials (** and *** denote p < 0.01 and p < 0.001, respectively).
Fig 3: AS-IV suppresses HCC growth and alleviates PD-L1-mediated immune suppression. (A) Tumour growth curves. (B) Tumours and tumour volumes after euthanising mice. (C) PD-L1 protein level assessment using Western blot. (D) IHC was employed to analyse the levels of PD-L1. (E) The effect of AS-IV on the level of miR-135b-5p in mouse tissues. (F) The effect of AS-IV on CNDP1 expression in mouse tissues. The uncropped blots are shown in the Supplemental Materials (*, **, and *** denote p < 0.05, p < 0.01, and p < 0.001, respectively).
Fig 4: Molecular schematic representation of AS-IV attenuating PD-L1-mediated immune suppression through the miR-135b-5p/CNDP1 axis.
Supplier Page from Abcam for Anti-CNDP1/CN1 antibody